Viking Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Viking Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Mar 7, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Mar 7, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Mar 21, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Mar 8, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $0 | Feb 7, 2024 |
| FY2021 | Dec 31, 2020 | $0 | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 13, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($359.64M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($109.96M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | ($85.90M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | ($68.87M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($54.99M) | Feb 7, 2024 |
| FY2021 | Dec 31, 2020 | ($39.50M) | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | ($25.78M) | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | ($22.06M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($20.58M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($14.73M) | Mar 7, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($393.34M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($150.92M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | ($100.83M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | ($70.36M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($55.68M) | Feb 7, 2024 |
| FY2021 | Dec 31, 2020 | ($42.66M) | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | ($32.69M) | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | ($26.16M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($19.07M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($13.85M) | Mar 7, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $344.96M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $101.64M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $63.81M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $54.23M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $44.98M | Feb 7, 2024 |
| FY2021 | Dec 31, 2020 | $31.93M | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $23.56M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $19.04M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $13.74M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $9.00M | Mar 7, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($278.69M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($87.79M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | ($73.38M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | ($48.40M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($47.59M) | Feb 7, 2024 |
| FY2021 | Dec 31, 2020 | ($21.78M) | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | ($24.75M) | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | ($18.76M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($14.76M) | Mar 13, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $715.73M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $908.32M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $368.49M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $168.53M | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | $210.66M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $256.50M | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $284.26M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $302.31M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $22.12M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $14.54M | Mar 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.67M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $28.04M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $20.07M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $23.21M | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | $8.78M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $12.16M | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $7.14M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $4.56M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $8.66M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $6.49M | Mar 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $639.06M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $880.28M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $348.42M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $145.32M | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | $201.88M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $244.34M | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $277.12M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $297.75M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $13.46M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $8.04M | Mar 7, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($847.55M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($487.91M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($377.94M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($292.05M) | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | ($223.18M) | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | ($168.19M) | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | ($128.70M) | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | ($102.92M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($80.86M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($60.28M) | Mar 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $165.81M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $26.68M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $55.52M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $36.63M | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | $26.37M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $29.12M | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $8.38M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $24.78M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $8.99M | Mar 13, 2019 |
| FY2018 | Dec 31, 2016 | $3.08M | Mar 13, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 7, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 7, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 114.79M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 111.57M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | 100.11M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 78.26M | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | 78.25M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | 73.22M | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | 72.41M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | 71.74M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 35.82M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | 20.82M | Mar 7, 2018 |